<DOC>
	<DOCNO>NCT02546375</DOCNO>
	<brief_summary>The purpose study describe efficacy safety bosutinib patient chronic myeloid leukaemia use real world set</brief_summary>
	<brief_title>A Study To Describe The Real World Use Of Bosutinib In The UK And Netherlands</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<criteria>Diagnosis Ph+ CML age â‰¥18 year bosutinib initiation . Prescribed bosutinib ( irrespective phase disease ) EITHER normal clinical practice since receive marketing authorisation ( 27th March 2013 ) EMA11 OR via compassionate use programme prior market authorization . Where require , evidence personally sign date informed consent document indicate patient ( legally acceptable representative ) inform pertinent aspect study . Prescribed bosutinib part interventional clinical trial programme . Initiated bosutinib le 3 month prior data collection take place .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Bosutinib</keyword>
	<keyword>chronic myeloid leukaemia</keyword>
	<keyword>retrospective</keyword>
	<keyword>observational</keyword>
</DOC>